Neowise Bio Completes Over RMB 200 Million Series B Financing to Advance TCR-T Therapies for Solid Tumors

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), nor does it represent the platform's position.Any article reprinted needs to be authorized.

Recently, Neowise Biotechnology, Co., Ltd. (hereinafter referred to as“Neowise Biotechnology”Or"Company"), a company focused on solid tumorsNeowise Biotechnology, Co., Ltd., an innovative enterprise in the development of TCR-T immunocyte therapeutic drugs, announced the completion of a Series B financing round exceeding 200 million yuan. This round of financing was led byApricot Capital and an industrial fundLed by, Delian, Yuanhe,Suzhou Angel Mother FundFollow-on investment, with existing shareholders Tonggao Capital and GEM continuing to support.

Neowise Biotechnology was founded inIn 2020, headquartered in Suzhou, Neowise Biotechnology is an innovative enterprise focused on the development of TCR-T immunotherapy drugs for solid tumors. Neowise Biotechnology has independently developed a high-throughput, high-sensitivity target antigen-natural TCR discovery platform, which efficiently screens for natural high-affinity TCR sequences that specifically recognize tumor antigens through iterative feedback combining computational and experimental validation, establishing a globally leading position.、Experimentally VerifiedTumorTarget Antigen-Natural TCR Pairing Database（CAST^®）The company currently has multiple pipelines that have advanced to the clinical trial stage. In clinical trials targeting various solid tumors, positive efficacy and good safety have been observed.

Among them,NW-101C is a self-developed, targeted product by the company.PRAME TCR-T Cell TherapyCandidate Drug, is the first product in China to enter the clinical stage for this target., has achieved positive efficacy in a variety of advanced solid tumors, and is currently undergoingPhase IRegistrationClinical research, with indications including ovarian cancer, malignant melanoma, esophageal squamous cell carcinoma, squamous cell carcinoma of the lung, soft tissue sarcoma, and triple-negative breast cancer, etc.

NW-301V isCompanySelf-developed, TargetedTCR-T Cell Therapy for KRAS G12V MutationCandidate drug, the preliminary clinical research results of which were presented as a proffered oral presentation at the 2025 ESMO Congress.proffered paper presentation) format, marking the world's first systematic disclosure of clinical data for a TCR-T drug targeting this specific site. As of July 2025, among the 14 evaluable patients with advanced colorectal cancer, pancreatic cancer, and others enrolled in the study, NW-301V demonstrated favorable safety and efficacy. In terms of safety, no dose-limiting toxicity or serious adverse reactions were observed. Regarding efficacy, an objective response rate (ORR) of 50% and a disease control rate (DCR) of 100% were achieved among the 10 subjects receiving medium and high-dose treatments.

CompanyThis round of financing will be mainly used for clinical research of core pipelines and the advancement of multiple pre-clinical pipelines, accelerating the company's innovative drugs towards clinical and commercialization.AndThe process of internationalization. With the support of this round of capital, Neowise Biotechnology will continue to expand its layout and benefit a large number of patients as soon as possible.

References:

Official Website